Effects of telmisartan combined with nifedipine controlled-release tablets on left ventricular function and inflammatory response in patients with coronary heart disease and mild to moderate hypertension
Objective To explore the effect of telmisartan combined with nifedipine controlled-release tablets on left ventricular function and inflammatory response in patients with coronary heart disease and mild to moderate hypertension.Methods 108 patients with coronary heart disease complicated with mild to moderate hypertension were randomly divided into a control group and an observation group,with 54 patients in each group.The control group was treated with nifedipine controlled-release tablets,and the observation group was treated with telmisartan.Comparison was made on blood pressure[diastolic blood pressure(DBP)and systolic blood pressure(SBP)],cardiac function[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)],inflammatory response[tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP)]and safety between the two groups.Results Before treatment,there was no significant difference in DBP and SBP between the two groups(P>0.05).After treatment,DBP of(78.22±6.79)mm Hg(1 mm Hg= 0.133 kPa)and SBP of(124.14±9.95)mm Hg in the observation group were lower than(84.57±8.02)and(140.69±11.20)mm Hg in the control group.The difference was statistically significant(P<0.05).Before treatment,there were no significant differences in LVEDD,LVEF and LVESD between the two groups(P>0.05).After treatment,LVEDD of(51.43±6.13)mm and LVESD of(43.13±6.97)mm in the observation group were lower than(54.13±5.89)and(46.42±6.95)mm in the control group;LVEF of(52.84±7.46)%in the observation group was higher than(49.48±6.97)%in the control group.There was statistical difference(P<0.05).Before treatment,there was no significant difference in the levels of TNF-α and hs-CRP between the two groups(P>0.05).After treatment,TNF-α of(39.38±9.85)ng/L and hs-CRP of(6.32±0.88)mg/L in the observation group were lower than(51.29±8.38)ng/L and(8.98±1.28)mg/L in the control group,and the difference was statistically significant(P<0.05).No serious adverse reactions occurred in both groups.Conclusion Telmisartan combined with nifedipine controlled-release tablets can effectively relieve inflammatory response,regulate blood pressure,improve cardiac function and have high safety in patients with coronary heart disease and mild to moderate hypertension.
Coronary heart diseaseMild to moderate hypertensionTelmisartanNifedipine controlled-release tabletsCardiac functionInflammatory response
万方数据
维普
